Switch theme
Sign up to access all valuation multiples
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
2004
n/a
Last FY Revenue $502M
Last FY EBITDA $110M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Shandong Weigao Blood achieved revenue of $502M and an EBITDA of $110M.
Shandong Weigao Blood expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shandong Weigao Blood valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $502M | XXX | XXX | XXX |
| Gross Profit | XXX | $212M | XXX | XXX | XXX |
| Gross Margin | XXX | 42% | XXX | XXX | XXX |
| EBITDA | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 22% | XXX | XXX | XXX |
| EBIT | XXX | $77.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | 15% | XXX | XXX | XXX |
| Net Profit | XXX | $62.6M | XXX | XXX | XXX |
| Net Margin | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Shandong Weigao Blood's stock price is CNY 40 (or $6).
Shandong Weigao Blood has current market cap of CNY 16.6B (or $2.3B), and EV of CNY 15.5B (or $2.2B).
See Shandong Weigao Blood trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Shandong Weigao Blood has market cap of $2.3B and EV of $2.2B.
Shandong Weigao Blood's trades at 4.3x EV/Revenue multiple, and 19.6x EV/EBITDA.
Equity research analysts estimate Shandong Weigao Blood's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shandong Weigao Blood's P/E ratio is not available.
See valuation multiples for Shandong Weigao Blood and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 19.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 27.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 37.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 39.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShandong Weigao Blood's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Shandong Weigao Blood's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shandong Weigao Blood's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shandong Weigao Blood and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shandong Weigao Blood acquired XXX companies to date.
Last acquisition by Shandong Weigao Blood was XXXXXXXX, XXXXX XXXXX XXXXXX . Shandong Weigao Blood acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Shandong Weigao Blood founded? | Shandong Weigao Blood was founded in 2004. |
| Where is Shandong Weigao Blood headquartered? | Shandong Weigao Blood is headquartered in China. |
| Is Shandong Weigao Blood publicy listed? | Yes, Shandong Weigao Blood is a public company listed on SHG. |
| What is the stock symbol of Shandong Weigao Blood? | Shandong Weigao Blood trades under 603014 ticker. |
| When did Shandong Weigao Blood go public? | Shandong Weigao Blood went public in 2025. |
| Who are competitors of Shandong Weigao Blood? | Similar companies to Shandong Weigao Blood include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Shandong Weigao Blood? | Shandong Weigao Blood's current market cap is $2.3B |
| Is Shandong Weigao Blood profitable? | Yes, Shandong Weigao Blood is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
